Breaking News, Financial News

Financial Report: Biogen Idec

Biogen Idec

4Q Revenues: $708 million (+12%)

4Q Earnings: $109 million (+95%)

FY Revenues: $2.68 billion (+11%)

FY Earnings: $218 million (+35%)

Comments: Revenues for the quarter and FY2006 included $218 million and $811 million, respectively, from Biogen’s joint business arrangement related to Rituxan. For the quarter, Avonex sales were up 6% to $439 million and for the year were up 11% to $1.7 billion. During 2006 the company launched Rituxan in rheumatoid arthritis and Tysabri in multiple sclerosis. R&D expenses for the quarter were $199.5 million, up 19% and $718.4 for the year, down 4%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters